Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management

Frontiers in Medicine

article

Mehdi Mirsaeidi¹  Marilyn K. Glassberg¹ 

[1] Division of Pulmonary, and Sleep Medicine, University of Miami Miller School of Medicine, United States

关键词: scleroderma;    interstitial lung disease;    systemic sclerosis;    cyclophosphamide;    nintedanib;    pirfenidone;   

DOI  :  10.3389/fmed.2019.00248

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

A subgroup of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), characterized by inflammation and progressive scarring of the lungs that can lead to respiratory failure. Although ILD remains the major cause of death in these individuals, there is no consensus statement regarding the classification and characterization of SSc-related ILD (SSc-ILD). Recent clinical trials address the treatment of SSc-ILD and the results may lead to new disease-altering therapies. In this review, we provide an update to the diagnosis, management and treatment of SSc-ILD.

【 授权许可】

CC BY